Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Martín Richard, Marta ^a   Massutí, Bartomeu ^b   Pineda, Eva ^c   Alonso, Vicente ^d   Marmol, Maribel ^e   Castellano, Daniel ^f   Fonseca, Emilio ^g   Galán, Antonio ^h   Llanos, Marta ⁱ   Sala, Maria Angeles ^j   Pericay, Carlos ^k   Rivera, Fernando ^l   Sastre, Javier ^m   Segura, Ángel ⁿ   Quindós, Maria ^o   Maisonobe, Pascal ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c IPSEN   (France)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL DE SAGUNTO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^j HOSPITAL DE BASURTO   (Spain)

^k Hospital Universitari de Sabadell   (Spain)

^l HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o Hospital A Coruna   (Spain)

more..

Author keywords

Antiproliferative effect; Lanreotide autogel; Neuroendocrine tumours; Phase II clinical trial; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; TUMOR MARKER;

ACUTE KIDNEY FAILURE; ADULT; AEROPHAGIA; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTHENIA; BREAST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EAR DISEASE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; IMAGE ANALYSIS; INFECTION; INJECTION SITE PAIN; INNER EAR DISEASE; KIDNEY DISEASE; MALE; METABOLIC DISORDER; MIDGUT; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OPEN STUDY; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIODIAGNOSIS; RADIOGRAPHY; RADIOLOGIST; SINGLE BLIND PROCEDURE; SKIN DISEASE; SPAIN; SUBCUTANEOUS FAT DISORDER; SYMPTOM; TREATMENT DURATION; TUMOR GROWTH; TUMOR LOCALIZATION; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; PEPTIDES, CYCLIC; SOMATOSTATIN; SPAIN; TREATMENT OUTCOME;

EID: 84884315127     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-427     Document Type: Article

References (33)

1. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003, 10:451-458. 10.1677/erc.0.0100451, 14713257.
2. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994, 135:2814-2817. 10.1210/en.135.6.2814, 7988476.
3. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010, 31:169-188.
4. Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D, Caron P, Pyronnet S. Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 2012, 97:727-737. 10.1210/jc.2011-2088, 22170729.
5. Castellano D, Grande E, Barriuso J. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med 2011, 364:1872-1873.
6. Capdevila J, Sevilla I, Alonso V, Anton-Aparico L, Jimenez-Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso-Guadalajara JD, Garcia-Alfonso P. Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): data from one Spanish cohort [abstract]. J Clin Oncol 2012, 30(Suppl):e14671.
7. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010, 16:2963-2970. 10.3748/wjg.v16.i24.2963, 2890935, 20572298.
8. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006, 17:1733-1742. 10.1093/annonc/mdl105, 16801334.
9. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies?. Endocr Relat Cancer 2007, 14:207-219. 10.1677/ERC-06-0061, 17639038.
10. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010, 139:742-753. 10.1053/j.gastro.2010.07.002, 20637207.
11. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R. PROMID Study Group Placebo-controlled, double-Blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009, 27:4656-4663. 10.1200/JCO.2009.22.8510, 19704057, PROMID Study Group.
12. Caplin M, Ruszniewski P, Pavel M, Cwikla J, Phan A, Raderer M, Sedlackova E, Cadiot G, Wall L, Rindi G, Liyanage N, Blumberg J. A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET) [abstract] http://eccamsterdam2013.ecco-org.eu/.
13. Faiss S, Pape U, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. International Lanreotide and Interferon Alfa Study Group Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. J Clin Oncol 2003, 21:2689-2696. 10.1200/JCO.2003.12.142, 12860945, International Lanreotide and Interferon Alfa Study Group.
14. Faiss S, Räth U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B. Ultra-High-dose lanreotide, treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999, 60:469-476. 10.1159/000007693, 10473972.
15. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997, 8:1041-1044. 10.1023/A:1008205415035, 9402179.
16. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993, 32:217-223. 10.3109/02841869309083915, 7686764.
17. Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, Milione M, Cattaruzza MS, Falconi M, David V, Ziparo V, Pederzoli P, Bordi C, Delle Fave G. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006, 17:461-466. 10.1093/annonc/mdj113, 16364959.
18. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F, Conte PF. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000, 23:412-415. 10.1097/00000421-200008000-00020, 10955874.
19. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000, 95:3276-3281. 10.1111/j.1572-0241.2000.03210.x, 11095353.
20. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EG, Oberg KE. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999, 17:1111.
21. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998, 93:1468-1471. 10.1111/j.1572-0241.1998.465_q.x, 9732927.
22. Ruszniewski P, Ducreux M, Chayvialle J, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Bernades P, Rougier P. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996, 39:279-283. 10.1136/gut.39.2.279, 1383312, 8977344.
23. Khan M, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (somatuline autogel). Aliment Pharmacol Ther 2011, 34:235-242. 10.1111/j.1365-2036.2011.04693.x, 21585408.
24. Bianchi A, De Marinis L, Fusco A, Lugli F, Tartaglione L, Milardi D, Mormando M, Lassandro AP, Paragliola R, Rota CA, Della Casa S, Corsello SM, Brizi MG, Pontecorvi A. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel. J Endocrinol Invest 2011, 34:692-697.
25. Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer 2006, 107:2474-2481. 10.1002/cncr.22272, 17054107.
26. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours, WHO international histological classification of tumours (ed 2) 2000, Berlin: Springer-Verlag.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
28. Barbanoj M, Antonijoan R, Morte A, Grinyó JM, Solà R, Vallès J, Peraire C, Cordero JA, Muñoz A, Jané F, Obach R. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clin Pharmacol Ther 1999, 66:485-491. 10.1016/S0009-9236(99)70011-1, 10579475.
29. Gomez-Panzani E, Chang S, Knowles N, Fohanno V. An ongoing, double-blind, randomized, placebo-controlled clinical trial investigating the efficacy and safety of somatuline® depot (lanreotide) injection in the treatment of carcinoid syndrome -- update on the current status [abstract] 2011, North American Neuroendocrine Tumor Society, Neuroendocrine Tumor Symposium [http://www.nanets.net/nanets_cd/2012/pdfs/O1gomezongoingtrial.pdf].
30. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. RADIANT-3 Study Group Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523. 10.1056/NEJMoa1009290, 21306238, RADIANT-3 Study Group.
31. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:501-513. 10.1056/NEJMoa1003825, 21306237.
32. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC. RADIANT-2 Study Group Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012. 10.1016/S0140-6736(11)61742-X, 22119496, RADIANT-2 Study Group.
33. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28:69-76. 10.1200/JCO.2009.24.2669, 19933912.